Genmab in-licenses antibody panel from Bristol-Myers

2 June 2015

Danish biotech firm Genmab (OMX: GEN) has entered into an agreement for an exclusive license from US pharma major Bristol-Myers Squibb (NYSE: BMY) to a panel of human antibodies targeting CD19 together with associated intellectual property.

The CD19 protein expressed on certain hematologic cancer cells is seen as a promising target for the treatment of these cancers, the company noted.

Genmab will make a one-time $4 million licensing payment to Bristol-Myers Squibb on the execution of the license. Other financial terms of the agreement were not disclosed. The deal is part of Genmab’s strategy to create a broad pipeline of innovative therapeutic products, using the company’s in house know-how and antibody expertise to create truly differentiated cancer therapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK